Cytosorbents (CTSO) Net Income towards Common Stockholders (2010 - 2026)

Cytosorbents (CTSO) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$5.1 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 246.79% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.8 million (up 26.44% YoY) and the FY2025 annual result came in at -$8.2 million, up 60.43% from the prior year.
• Net Income towards Common Stockholders rose to -$5.1 million in Q1 2026, from -$5.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $1.9 million in Q2 2025 to a low of -$12.2 million in Q3 2022.
• A 5-year average of -$5.6 million and a median of -$5.8 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 661.61% — and 2025, when it jumped 145.34%.
• Tracing CTSO's Net Income towards Common Stockholders over 5 years: stood at -$766128.0 in 2022, then sank by 661.61% to -$5.8 million in 2023, then slipped by 29.69% to -$7.6 million in 2024, then advanced by 27.36% to -$5.5 million in 2025, then advanced by 6.69% to -$5.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$5.1 million (Q1 2026), -$5.5 million (Q4 2025), and -$3.2 million (Q3 2025), per Business Quant data.